PolTREG appoints Dan Shelly as Main Enterprise Improvement

Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a medical-phase biotechnology organization producing mobile therapies for a huge array of autoimmune disorders, announces currently it has appointed Prof. Daniel Shelly, PhD, MBA, into the job of Chief Small business Advancement Officer, to enable PolTREG make the strategic, commercial, exploration and pharmaceutical partnerships that will enable the corporation to correctly commercialise its powerful pipeline of mobile therapies for disorders such as Style-1 Diabetic issues (T1D), Numerous Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS).

“I am elated we were in a position to attract Dan to enable us supply the guarantee of Treg mobile therapies for a wide variety of autoimmune illnesses. PolTREG has the most detailed pipeline of mobile therapies for autoimmune health conditions, which includes Form-1 Diabetic issues and Many Sclerosis, and Dan’s arrival will permit us to go on to supply the milestones that will carry our lead assets nearer to industry,” explained Prof. Piotr Trzonkowski, Chief Govt Officer of PolTREG.

Dr Shelly is an astute veteran of the lifestyle science market, with a deep comprehension of biology and the Treg cell therapies that PolTREG is creating. He has a verified track document of closing small business improvement deals for a vast array of biotech corporations, including most not long ago numerous early-stage evaluation deals for Prescient Therapeutics Ltd., a clinical stage oncology business building personalised drugs techniques to most cancers, making use of Car-T technologies. He was Director of World wide Small business Growth and Strategic Partnerships for the world non-gain Route, wherever he was the Co-Direct for the COVID-19 endeavor force. He is an adjunct affiliate professor at the College of Cincinnati, in which he teaches biologics discovery, pharmaco-economics and biotech company, publishes in scientific journals, and is a usually invited speaker and believed leader at worldwide mobile remedy conferences. Dr Shelly has a detailed knowledge of the medical improvement pathway, with direct expertise of regulatory submissions, and is qualified in scientific asset valuation and due diligence.

PolTREG boasts the most advanced pipeline for Treg cell therapies in autoimmune disorder, with its direct applicant, PTG-007, in mid-phase medical scientific tests in T1D and MS. In addition, the firm expects to start To start with-in-Human scientific trials of its Car-Tregs for two neurodegenerative diseases – MS and ALS – in early 2025.

Complementing PolTREG’s progressive scientific pipeline is the the latest opening of a single of Europe’s biggest CGMP cell remedy producing facilities. The facility, 1 of the most sophisticated of its sort, will have more than 2,100 sqm of laboratory room, such as 15 operational generation traces, a capability that can be drastically further expanded. The facility by now can provide existence-strengthening cell therapies any place in Europe inside of 24 hours post manufacturing.

PolTREG was the initially organization in the world to administer Treg therapies to patients and the 1st to start acquiring revenues from its lead solution. So much, PolTREG has efficiently treated 27 sufferers with PTG-007 commercially underneath a clinic exemption plan in Poland.

About PolTREG
PolTREG is a world-wide leader in building autoimmune therapies centered on T-regulatory cells (Tregs). Its guide product, PTG-007, autologous Treg cure for early-onset Form-1 Diabetes (T1D) is completely ready for Phase 2/3 clinical testing, for which the business is seeking a partnership. The business will launch Period 2 trials for PTG-007 to deal with Various Sclerosis (MS) in the second fifty percent of 2024, for RRMS and PPMS. PolTREG also has engineered Tregs, including Vehicle-Tregs, antigen-specific Tregs and TCR-Tregs, in the preclinical stage. PolTREG  has done four scientific trials with far more than 100 sufferers taken care of with Tregs.

For much more data be sure to go to www.poltreg.com.

For further information and facts remember to get hold of:

Essential info
The contents of this announcement contain statements that are, or may perhaps be deemed to be, “ahead-searching statements”. These ahead-on the lookout statements can be discovered by the use of ahead-hunting terminology, including the terms “believes”, “estimates,” “anticipates”, “expects”, “intends”, “could”, “will”, “strategies”, “go on”, “ongoing”, “probable”, “predict”, “task”, “goal”, “look for” or “ought to”, and include things like statements the Firm can make regarding the intended success of its method. By their nature, ahead-on the lookout statements require risks and uncertainties and visitors are cautioned that any this kind of forward-wanting statements are not guarantees of long run performance. The firm’s actual final results may vary materially from those people predicted by the ahead-searching statements. The organization undertakes no obligation to publicly update or revise forward-seeking statements, except as may be essential by regulation.

• 20240216 PolTREG PR Dan Shelly – accepted
• Daniel Shelly